Research synthesisModerate evidenceModerate effect8 studies · 7 beneficial · 1 neutral · 0 harmful
Across 8 studies, 7 reported beneficial effects, with effect sizes ranging from small to moderate. The predominant effect size is moderate, with the strongest evidence supporting reductions in low-density lipoprotein cholesterol (LDL-C). The typical dose studied was around 500–1000 mg/day, with effects observed over a median duration of 12 weeks. The most-studied population was adults with metabolic conditions including hyperlipidemia, MASLD, and type 2 diabetes.
- Effective dose range: 500–1200 mg/day (typically 500 mg twice daily or 1 g/day)
- Studied populations: Adults with hyperlipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes, and obesity.
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). One well-designed RCT (2021) with 84 participants found a neutral effect on LDL-C, introducing some uncertainty. Many studies had small sample sizes or combined berberine with other interventions, complicating dose–effect estimates.
Generated Jul 15, 2026